Avantor (AVTR) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales were $1.683 billion, down 1% year-over-year, with organic revenue flat; adjusted EBITDA was $279.8 million (16.6% margin), and adjusted EPS was $0.24.

• Net income declined to $64.7 million from $92.9 million year-over-year.

• Free cash flow for Q2 was $125 million, with 100% conversion; operating cash flow was $154.4 million.

• CEO transition announced: Emmanuel Ligner to succeed Michael Stubblefield effective August 18, 2025.

• Divestiture of Clinical Services created a $48 million revenue headwind and $0.01 EPS dilution in the quarter.

Financial highlights

• Q2 2025 net sales: $1,683.4 million, down 1.1% year-over-year; organic net sales down 0.2%.

• Adjusted gross profit: $554 million (32.9% margin), down 120–130 bps year-over-year.

• Adjusted EBITDA: $279.8 million (16.6% margin), down from $306 million (17.9%) in Q2 2024.

• Adjusted operating income: $252.2 million (15.0% margin), down from $277 million (16.3%).

• Free cash flow: $125 million, down from $235 million year-over-year.

Outlook and guidance

• Full-year organic revenue growth guidance reduced to -2% to flat (from -1% to +1%).

• Adjusted EBITDA margin guidance: 16.5%–17%; adjusted EPS: $0.94–$0.98.

• Free cash flow guidance lowered to $550–$600 million before transformation expenses.

• Q3 organic revenue growth expected at -4% to -2%, with both segments down.

• Reported revenue range reflects a 2% headwind from Clinical Services divestiture and 1% FX tailwind.